Injections with doses of the Pfizer-BioNTech Comirnaty coronavirus disease (COVID-19) vaccine are pictured in Berlin. (Photo: Reuters) Injections with doses of the Pfizer-BioNTech Comirnaty coronavirus disease (COVID-19) vaccine are pictured in Berlin. (Photo: Reuters)The European Medicines Agency on Monday started reviewing a low-dose version of BioNTech and Pfizer's COVID-19 vaccine for use in children between the age of six months and four years.
Last month the U.S Centers for Disease Control and Prevention cleared the way for use of the shot in children of that age group in the United States.
Pfizer and BioNTech filed for approval in Europe in the age group on July 8, proposing a three-shot course with a 3 microgram dosage, which is a fraction of the 30 micrograms used on adults.
Infosys shares: Brokerages see up to 19% upside on strong AI-led deal momentum
Angel One share: What MOFSL says post Q3 results, stock split, dividend declaration
Air India 171 probe: AAIB rejects pilots' body objection, says it can examine anyone in the case
Troops from several European nations arrive in Greenland amid US’ ‘technical talks’
Jio Platforms IPO: Reliance Q3 results today; key things to watch for digital business
GST Cut Caused Short-Term Pain, But Used-Car Market Disruption Has Begun: CARS24 CFO
Is Simple Energy's New Launch Worth A Buy? Let's Test It!
Chennai Sangamam Lights Up Pongal With Music, Folk Arts And A Grand Celebration Of Tamil Culture
Sadaf Sayeed On Gold, Silver Rally | What Microfinanciers Expect From Budget 2026
New CPI, GDP Series To Help RBI Balance Inflation And Growth: RBI GUV Sanjay Malhotra
Infosys shares jump 5%: How much Narayana Murthy family, LIC, small investors gained
South Indian Bank shares hit record high on Q3 earnings, more details 
Delta Corp Q3 earnings: Shares fall 4%, firm cites this factor for weak show Jio Platforms IPO: Reliance Q3 results today; key things to watch for digital business
Stock market: Sensex jumps 343 pts, Nifty tops 25,700; Infosys, Tech Mahindra lead gainers